Empery Asset Management, LP
stated that they own a 5.5% stake in OpGen, Inc. (NASDAQ:OPGN) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission on Tuesday, July 18th. The investor owns 2,500,000 shares of the stock worth $680,500. The reporting parties listed on the disclosure included Empery Asset Management, LP, Ryan M Lane and Martin D Hoe. The filing is available through the SEC website at this hyperlink.
Empery Asset Management, LP
provided the following explanation of their ownership:
Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Warning: file_get_contents(https://whalewisdom.com
2,500,000
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6
Shares of OpGen, Inc. (NASDAQ OPGN) opened at 0.2722 on Friday. OpGen, Inc. has a one year low of $0.26 and a one year high of $3.10. The stock has a 50 day moving average of $0.43 and a 200-day moving average of $0.83. The company’s market capitalization is $14.03 million.
Several equities research analysts recently commented on the stock. HC Wainwright set a $1.00 price objective on shares of OpGen and gave the company a “buy” rating in a research report on Wednesday. Dawson James reaffirmed a “buy” rating on shares of OpGen in a research report on Monday, June 19th. Finally, Zacks Investment Research cut shares of OpGen from a “buy” rating to a “sell” rating in a research report on Tuesday, May 2nd.
In other news, CFO Timothy C. Dec acquired 65,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The stock was bought at an average cost of $0.40 per share, with a total value of $26,000.00. Following the completion of the purchase, the chief financial officer now directly owns 118,966 shares of the company’s stock, valued at $47,586.40. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Jven Capital, Llc acquired 1,875,000 shares of the company’s stock in a transaction on Tuesday, July 18th. The shares were purchased at an average cost of $0.40 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here. Company insiders own 53.27% of the company’s stock.
OpGen Company Profile
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
